6,116 Shares in Revolution Medicines, Inc. $RVMD Bought by Bayforest Capital Ltd

Bayforest Capital Ltd acquired a new position in shares of Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 6,116 shares of the company's stock, valued at approximately $225,000.

Several other large investors have also modified their holdings of RVMD. CWM LLC boosted its holdings in shares of Revolution Medicines by 171.3% during the 2nd quarter. CWM LLC now owns 917 shares of the company's stock worth $34,000 after buying an additional 579 shares during the period. Banque Transatlantique SA bought a new stake in Revolution Medicines in the 1st quarter valued at $42,000. Quarry LP bought a new stake in Revolution Medicines in the 1st quarter valued at $50,000. Twin Tree Management LP bought a new stake in Revolution Medicines in the 1st quarter valued at $58,000. Finally, Goodman Advisory Group LLC bought a new stake in Revolution Medicines in the 1st quarter valued at $127,000. 94.34% of the stock is owned by institutional investors.

Insider Activity at Revolution Medicines

In related news, insider Stephen Michael Kelsey sold 100,000 shares of Revolution Medicines stock in a transaction dated Thursday, September 11th. The shares were sold at an average price of $44.08, for a total transaction of $4,408,000.00. Following the completion of the transaction, the insider directly owned 289,414 shares of the company's stock, valued at $12,757,369.12. This trade represents a 25.68% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Jack Anders sold 5,238 shares of Revolution Medicines stock in a transaction dated Wednesday, September 3rd. The shares were sold at an average price of $40.17, for a total transaction of $210,410.46. Following the transaction, the chief financial officer directly owned 113,314 shares of the company's stock, valued at $4,551,823.38. This represents a 4.42% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 188,033 shares of company stock worth $8,456,208 in the last ninety days. Company insiders own 8.20% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the stock. The Goldman Sachs Group increased their price target on shares of Revolution Medicines from $65.00 to $73.00 and gave the company a "buy" rating in a report on Friday, September 12th. Wells Fargo & Company increased their price target on shares of Revolution Medicines from $67.00 to $70.00 and gave the company an "overweight" rating in a report on Thursday, September 11th. Lifesci Capital assumed coverage on shares of Revolution Medicines in a report on Monday, August 18th. They issued an "outperform" rating and a $80.00 price target for the company. Raymond James Financial assumed coverage on shares of Revolution Medicines in a report on Friday, September 12th. They issued a "strong-buy" rating and a $72.00 price target for the company. Finally, Stifel Nicolaus assumed coverage on shares of Revolution Medicines in a report on Wednesday. They issued a "buy" rating and a $85.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, Revolution Medicines currently has an average rating of "Moderate Buy" and a consensus target price of $76.14.

Revolution Medicines Price Performance

NASDAQ:RVMD opened at $49.68 on Friday. The company has a 50-day moving average of $42.01 and a 200-day moving average of $39.42. The company has a market capitalization of $9.29 billion, a price-to-earnings ratio of -11.04 and a beta of 1.27. Revolution Medicines, Inc. has a 52 week low of $29.17 and a 52 week high of $62.40. The company has a debt-to-equity ratio of 0.13, a quick ratio of 11.79 and a current ratio of 11.79.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported ($1.31) EPS for the quarter, missing analysts' consensus estimates of ($0.94) by ($0.37). Revolution Medicines's revenue was up .0% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.81) EPS. As a group, equities research analysts anticipate that Revolution Medicines, Inc. will post -3.49 earnings per share for the current fiscal year.

Revolution Medicines Company Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.

Want to see what other hedge funds are holding RVMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.